Located in Zhangjiang High-Tech Park, Pudong New Area, Shanghai. Shanghai De Novo Pharmatech Co., Ltd. is a science driven, innovation oriented clinical stage Biotech company aiming to bring novel tumor treatment with first-in-class and best-in-class assets discovered in-house.   

The R&D team is led by industrial veterans. The R&D leadership team members have rich experience in medicinal chemistry, discovery biology, translational medicine, IND enabling and clinical development.

Following the latest understanding of cancer biology, Shanghai De Novo Pharmatech focuses on both innate immunity modulation and target therapy for drug discovery and development.

 l  Innate immune modulation

The success of anti-PD1/PD-L1 in cancer treatment has claimed the initiation of a cancer immunotherapy era and has attracted intensive exploration in T cell modulation for novel drug discovery and development. As a conserved defense system, innate immunity remains to be exploited for cancer immunotherapy. In synergy with adaptive immunity, innate immunity plays a critical role to eradicate external pathogens and tumor cells. Upon binding to corresponding ligands/agonists, pattern recognition receptor family such as Toll-like receptors has been demonstrated to turn on a series of proinflammatory events including cytokine secretion, phagocytosis and antigen presentation. Synergy with anti-PD1/PD-L1 is expected to bring clinical benefits to tumor patients.

Shanghai De Novo Pharmatech has discovered TLR8 selective agonist and STING agonist in-house. Both assets are in phase 1 clinical development as monotherapy and in combination with anti-PD1 Ab.

To maximize potential therapeutic window, the discovery team has built a linker-innate immune agonist platform to facilitate discovery and development of a new type of ADC, called ISAC (Immune Stimulating Antibody Conjugates).

 l Targeted therapy

Two orally available DNA damage response (DDR) pathway inhibitors, targeting ATR and Wee1 respectively, are now in discovery stage. In preclinical models, ATR inhibitor candidate hasdemonstrated superior anti-tumor efficacy and satisfied pharmacokinetic profiles.

The company has been dedicated to the discovery and development of innovative anti-cancer therapeutics with globalrights, building a global leading pipeline to generate effective therapeutics solutions and benefit patients.